Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

BENGALURU, India, Feb. 8, 2024 /PRNewswire/ — Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG (‘Sandoz’) which provides Sandoz the exclusive rights to…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.